Veritable L.P. lifted its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,633 shares of the medical equipment provider’s stock after purchasing an additional 538 shares during the period. Veritable L.P.’s holdings in Zimmer Biomet Holdings were worth $1,237,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Enterprise Financial Services Corp raised its stake in shares of Zimmer Biomet Holdings by 0.3% during the 2nd quarter. Enterprise Financial Services Corp now owns 2,646 shares of the medical equipment provider’s stock worth $340,000 after purchasing an additional 9 shares during the period. Sandy Spring Bank raised its stake in shares of Zimmer Biomet Holdings by 1.7% during the 1st quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock worth $149,000 after purchasing an additional 20 shares during the period. Parkside Financial Bank & Trust raised its stake in shares of Zimmer Biomet Holdings by 2.7% during the 1st quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock worth $102,000 after purchasing an additional 22 shares during the period. Cleararc Capital Inc. raised its stake in shares of Zimmer Biomet Holdings by 0.5% during the 1st quarter. Cleararc Capital Inc. now owns 4,897 shares of the medical equipment provider’s stock worth $598,000 after purchasing an additional 25 shares during the period. Finally, CWA Asset Management Group LLC raised its stake in shares of Zimmer Biomet Holdings by 1.8% during the 2nd quarter. CWA Asset Management Group LLC now owns 1,952 shares of the medical equipment provider’s stock worth $251,000 after purchasing an additional 34 shares during the period. Institutional investors own 85.35% of the company’s stock.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) opened at 115.92 on Thursday. The stock has a market cap of $23.44 billion, a price-to-earnings ratio of 33.02 and a beta of 1.21. Zimmer Biomet Holdings, Inc. has a one year low of $95.63 and a one year high of $133.49. The stock’s 50 day moving average price is $114.50 and its 200 day moving average price is $120.75.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing the consensus estimate of $2.10 by ($0.02). Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The company had revenue of $1.95 billion during the quarter, compared to the consensus estimate of $1.95 billion. During the same period last year, the business earned $2.02 EPS. The firm’s quarterly revenue was up 1.1% compared to the same quarter last year. Equities analysts predict that Zimmer Biomet Holdings, Inc. will post $8.24 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 22nd will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.84%. The ex-dividend date is Thursday, September 21st. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is currently 27.59%.

TRADEMARK VIOLATION WARNING: This article was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/09/28/zimmer-biomet-holdings-inc-zbh-stake-raised-by-veritable-l-p.html.

A number of equities research analysts recently issued reports on ZBH shares. Stifel Nicolaus restated a “hold” rating and issued a $125.00 price objective on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Gabelli started coverage on Zimmer Biomet Holdings in a research note on Thursday, August 24th. They issued a “buy” rating and a $142.00 price objective on the stock. Zacks Investment Research cut Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 8th. BMO Capital Markets restated a “buy” rating and issued a $136.00 price objective on shares of Zimmer Biomet Holdings in a research note on Tuesday, July 11th. Finally, Wells Fargo & Company restated a “market weight” rating on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Zimmer Biomet Holdings has an average rating of “Hold” and a consensus target price of $136.58.

In related news, VP Tony W. Collins sold 16,986 shares of Zimmer Biomet Holdings stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $121.74, for a total transaction of $2,067,875.64. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.07% of the stock is owned by company insiders.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.